(Alliance News) - GSK PLC on Thursday said the prefilled syringe version of its vaccine Shingrix has been approved for use in the US for the prevention of shingles.

London: GSK plc has received approval from the US Food and Drug Administration (FDA) for a prefilled syringe presentation of ...

Prefilled syringe presentation offers a convenient administration option to healthcare professionals·         An estimated one million people develop shingles in the US each year[1]GSK plc ...

GSK announced on Thursday that it has received approval from the US Food and Drug Administration for a new prefilled syringe presentation of its shingles vaccine, Shingrix.

The Save the Children Immunisation Accelerator has opened a second round of applications, inviting organisations in Nigeria and Ethiopia to submit proposals for innovations that tackle entrenched ...

AWS beleives AI agents will change how enterprises work and with its new Amazon Bedrock AgentCore, it hopes to make it easier ...

This summary highlights significant events in the health sector, including Johnson & Johnson's profit boost from Darzalex, safety concerns for GSK's cancer drug, refugee malnutrition in Gaza, KKR's ...

J&J (NYSE:JNJ) stock surges rallying peers despite Trump's latest tariff threats on pharma as the company posts a quarterly ...

GSK PLC closed 15.32% short of its 52-week high of £16.79, which the company reached on September 9th.

From my colleague Drew Joseph: Ahead of an advisory committee meeting Thursday focused on GSK’s multiple myeloma drug Blenrep, the FDA pointed to concerns about the high rates of eye issues that have ...

Recent health headlines include FDA's eye safety concerns over GSK's cancer drug, escalating malnutrition rates in Gaza ...

PDUFA date nears for GSK plc’s Blenrep (belantamab mafodotin), the U.S. FDA’s Oncologic Drugs Advisory Committee will decide July 17 on whether available data justify the return to market of the ...